Atrial therapies reduce atrial arrhythmia burden in defibrillator patients

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Atrial tachyarrhythmias are common in patients receiving implantable cardioverter-defibrillators (ICDs) for ventricular tachyarrhythmias.
• Approximately 25% of ICD recipients have pre-existing atrial tachyarrhythmias.

Purpose of the Study:

• To evaluate the efficacy of device-based atrial therapies in reducing the burden of spontaneous atrial tachyarrhythmias.
• To assess the impact of pacing and shock therapies on atrial arrhythmia burden.

Main Methods:

• A multicenter trial randomized patients with ICDs and a history of atrial tachyarrhythmias to periods with atrial therapies "on" or "off".
• Dual-chamber ICDs with atrial pacing and shock capabilities were utilized.
• Analysis included 52 patients with sufficient follow-up data.

Main Results:

• Atrial therapies led to a significant reduction in atrial tachyarrhythmia burden, from a mean of 58.5 to 7.8 hours per month.
• This reduction was statistically significant (P=0.007).
• Atrial pacing therapies alone also demonstrated a significant reduction in burden (P=0.01).

Conclusions:

• Device-based atrial pacing and shock therapies effectively reduce atrial tachyarrhythmia burden in patients with standard ICD indications.
• These findings support the use of integrated atrial therapies for managing arrhythmias in ICD patients.